Science 9 January 1987: Vol. 235. no. 4785, pp. 177 - 182 DOI: 10.1126/science.3798106

Prev | Table of Contents | Next

Articles

PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis.

B. Schade, T. Rao, N. Dourdin, R. Lesurf, M. Hallett, R. D. Cardiff, and W. J. Muller (2009)
J. Biol. Chem. 284, 19018-19026
 |  Abstract »  |  Full Text »  |  PDF »

Justification of the Change From 10% to 30% for the Immunohistochemical HER2 Scoring Criterion in Breast Cancer.

Y.-H. Liu, F.-P. Xu, J.-Y. Rao, H.-G. Zhuang, X.-L. Luo, L. Li, D.-L. Luo, F. Zhang, and J. Xu (2009)
Am J Clin Pathol 132, 74-79
 |  Abstract »  |  Full Text »  |  PDF »

Automated Cellular Imaging System III for Assessing HER2 Status in Breast Cancer Specimens: Development of a Standardized Scoring Method That Correlates With FISH.

D. M. Minot, B. R. Kipp, R. M. Root, R. G. Meyer, C. A. Reynolds, A. Nassar, M. R. Henry, and A. C. Clayton (2009)
Am J Clin Pathol 132, 133-138
 |  Abstract »  |  Full Text »  |  PDF »

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

M. Arnedos, A. Nerurkar, P. Osin, R. A'Hern, I. E. Smith, and M. Dowsett (2009)
Ann. Onc.
 |  Abstract »  |  Full Text »  |  PDF »

What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?.

C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero (2009)
Ann. Onc. 20, 1157-1162
 |  Abstract »  |  Full Text »  |  PDF »

Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy.

R. M. Reilly (2009)
J. Nucl. Med. 50, 1017-1019
 |  Full Text »  |  PDF »

Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT.

S. Nimmagadda, M. Pullambhatla, and M. G. Pomper (2009)
J. Nucl. Med. 50, 1124-1130
 |  Abstract »  |  Full Text »  |  PDF »

Cell Lines as Candidate Reference Materials for Quality Control of ERBB2 Amplification and Expression Assays in Breast Cancer.

Y. Xiao, X. Gao, S. Maragh, W. G. Telford, and A. Tona (2009)
Clin. Chem. 55, 1307-1315
 |  Abstract »  |  Full Text »  |  PDF »

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, et al. (2009)
PNAS 106, 10284-10289
 |  Abstract »  |  Full Text »  |  PDF »

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial.

M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja, U. Dafni, J. Rueschoff, B. Jordan, S. Dolci, M. Abramovitz, O. Stoss, et al. (2009)
J. Clin. Oncol. 27, 2962-2969
 |  Abstract »  |  Full Text »  |  PDF »

HER-2/neu analysis in breast cancer bone metastases.

J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al. (2009)
J. Clin. Pathol. 62, 542-546
 |  Abstract »  |  Full Text »  |  PDF »

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging.

E. C.F. Dijkers, J. G.W. Kosterink, A. P. Rademaker, L. R. Perk, G. A.M.S. van Dongen, J. Bart, J. R. de Jong, E. G.E. de Vries, and M. N. Lub-de Hooge (2009)
J. Nucl. Med. 50, 974-981
 |  Abstract »  |  Full Text »  |  PDF »

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

K. L. Blackwell, M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein (2009)
Ann. Onc. 20, 1026-1031
 |  Abstract »  |  Full Text »  |  PDF »

Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane.

A. Moreno-Aspitia and E. A. Perez (2009)
Mayo Clin. Proc. 84, 533-545
 |  Abstract »  |  Full Text »  |  PDF »

Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer.

C. Shimizu, N. Masuda, K. Yoshimura, H. Tsuda, M. Mano, M. Ando, K. Tamura, and Y. Fujiwara (2009)
Jpn. J. Clin. Oncol.
 |  Abstract »  |  Full Text »  |  PDF »

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2.

M. Jager, A. Schoberth, P. Ruf, J. Hess, and H. Lindhofer (2009)
Cancer Res. 69, 4270-4276
 |  Abstract »  |  Full Text »  |  PDF »

Adiponectin Deficiency Limits Tumor Vascularization in the MMTV-PyV-mT Mouse Model of Mammary Cancer.

M. S. Denzel, L. W. Hebbard, G. Shostak, L. Shapiro, R. D. Cardiff, and B. Ranscht (2009)
Clin. Cancer Res. 15, 3256-3264
 |  Abstract »  |  Full Text »  |  PDF »

Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers.

D. J. Slamon and M. F. Press (2009)
J Natl Cancer Inst 101, 615-618
 |  Full Text »  |  PDF »

Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification: Evaluation According to ASCO/CAP Criteria.

M. Brunelli, E. Manfrin, G. Martignoni, K. Miller, A. Remo, D. Reghellin, S. Bersani, S. Gobbo, A. Eccher, M. Chilosi, et al. (2009)
Am J Clin Pathol 131, 678-682
 |  Abstract »  |  Full Text »  |  PDF »

Finding Biomarkers of Cancer Drug Resistance through RNA Interference-Based Genetic Screens.

R. Bernards (2009)
Am. Assoc. Cancer Res. Educ. Book 2009, 253-257
 |  Full Text »  |  PDF »

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al. (2009)
Clin. Cancer Res. 15, 2895-2904
 |  Abstract »  |  Full Text »  |  PDF »

Tumor detection and elimination by a targeted gallium corrole.

H. Agadjanian, J. Ma, A. Rentsendorj, V. Valluripalli, J. Y. Hwang, A. Mahammed, D. L. Farkas, H. B. Gray, Z. Gross, and L. K. Medina-Kauwe (2009)
PNAS 106, 6105-6110
 |  Abstract »  |  Full Text »  |  PDF »

Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations.

Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige (2009)
Am J Clin Pathol 131, 490-497
 |  Abstract »  |  Full Text »  |  PDF »

Review Article: Targeted Therapy: Comprehensive Review.

R. L. Barros Costa (2009)
American Journal of Hospice and Palliative Medicine 26, 137-146
 |  Abstract »  |  PDF »

Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer.

S. Lennon, C. Barton, L. Banken, L. Gianni, M. Marty, J. Baselga, and B. Leyland-Jones (2009)
J. Clin. Oncol. 27, 1685-1693
 |  Abstract »  |  Full Text »  |  PDF »

Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients.

A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett (2009)
J. Clin. Oncol. 27, 1694-1705
 |  Abstract »  |  Full Text »  |  PDF »

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine.

J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi (2009)
Oncologist 14, 320-368
 |  Abstract »  |  Full Text »  |  PDF »

Memo is a cofilin-interacting protein that influences PLC{gamma}1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration.

M. Meira, R. Masson, I. Stagljar, S. Lienhard, F. Maurer, A. Boulay, and N. E. Hynes (2009)
J. Cell Sci. 122, 787-797
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 as a Target for Breast Cancer Therapy.

M. Ignatiadis, C. Desmedt, C. Sotiriou, E. de Azambuja, and M. Piccart (2009)
Clin. Cancer Res. 15, 1848-1852
 |  Full Text »  |  PDF »

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients.

K. M. Koch, N. J. Reddy, R. B. Cohen, N. L. Lewis, B. Whitehead, K. Mackay, A. Stead, A. P. Beelen, and L. D. Lewis (2009)
J. Clin. Oncol. 27, 1191-1196
 |  Abstract »  |  Full Text »  |  PDF »

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations.

G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press (2009)
J. Clin. Oncol. 27, 1323-1333
 |  Abstract »  |  Full Text »  |  PDF »

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis.

T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela (2009)
PNAS 106, 3294-3299
 |  Abstract »  |  Full Text »  |  PDF »

Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.

C. F Singer, G. Hudelist, E.-M. Fuchs, W. Kostler, A. Fink-Retter, D. Gschwantler-Kaulich, M. Gnant, W. Lamm, M. Rudas, K. Czerwenka, et al. (2009)
Endocr. Relat. Cancer 16, 73-83
 |  Abstract »  |  Full Text »  |  PDF »

Association between frequent CpG island methylation and HER2 amplification in human breast cancers.

K. Terada, E. Okochi-Takada, S. Akashi-Tanaka, K. Miyamoto, K. Taniyama, H. Tsuda, K. Asada, M. Kaminishi, and T. Ushijima (2009)
Carcinogenesis 30, 466-471
 |  Abstract »  |  Full Text »  |  PDF »

Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9.

L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al. (2009)
Clin. Cancer Res. 15, 1575-1584
 |  Abstract »  |  Full Text »  |  PDF »

Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.

Y. H. Choi, J. H. Ahn, S.-B. Kim, K.-H. Jung, G.-Y. Gong, M.-J. Kim, B.-H. Son, S.-H. Ahn, and W. K. Kim (2009)
Ann. Onc.
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen.

G. Sabnis, A. Schayowitz, O. Goloubeva, L. Macedo, and A. Brodie (2009)
Cancer Res. 69, 1416-1428
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors.

M. M. Seavey, Z.-K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi (2009)
Clin. Cancer Res. 15, 924-932
 |  Abstract »  |  Full Text »  |  PDF »

The Clinical Utility of Tumor Markers.

B. Handy (2009)
Lab Med 40, 99-103
 |  Abstract »  |  Full Text »  |  PDF »

Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review.

A. L. Chan, H. W. Leung, C.-L. Lu, and S. J. Lin (2009)
Ann. Pharmacother. 43, 296-303
 |  Abstract »  |  Full Text »  |  PDF »

Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways.

L. I. Gordon, M. A. Burke, A. T. K. Singh, S. Prachand, E. D. Lieberman, L. Sun, T. J. Naik, S. V. N. Prasad, and H. Ardehali (2009)
J. Biol. Chem. 284, 2080-2087
 |  Abstract »  |  Full Text »  |  PDF »

Effect of Lapatinib on the Development of Estrogen Receptor-Negative Mammary Tumors in Mice.

T. E. Strecker, Q. Shen, Y. Zhang, J. L. Hill, Y. Li, C. Wang, H.-T. Kim, T. M. Gilmer, K. R. Sexton, S. G. Hilsenbeck, et al. (2009)
J Natl Cancer Inst 101, 107-113
 |  Abstract »  |  Full Text »  |  PDF »

Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort.

S. Sieri, V. Krogh, G. Bolelli, C. A. Abagnato, S. Grioni, V. Pala, A. Evangelista, C. Allemani, A. Micheli, G. Tagliabue, et al. (2009)
Cancer Epidemiol. Biomarkers Prev. 18, 169-176
 |  Abstract »  |  Full Text »  |  PDF »

Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice.

O. Radkevich-Brown, J. Jacob, M. Kershaw, and W.-Z. Wei (2009)
Cancer Res. 69, 212-218
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.

I. H. Park, J. Ro, K. S. Lee, B. H. Nam, Y. Kwon, and K. H. Shin (2009)
Ann. Onc. 20, 56-62
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 Targeting Agents and Antiangiogenic Therapy: Evolution of Adjuvant Therapy in Breast Cancer.

S. Sinclair, A. S. Zimmer, and S. M. Swain (2009)
ASCO Educational Book 2009, 3-10
 |  Abstract »  |  Full Text »  |  PDF »

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors.

A. Coxon, T. Bush, D. Saffran, S. Kaufman, B. Belmontes, K. Rex, P. Hughes, S. Caenepeel, J. B. Rottman, A. Tasker, et al. (2009)
Clin. Cancer Res. 15, 110-118
 |  Abstract »  |  Full Text »  |  PDF »

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study.

J. Cortes, S. Di Cosimo, M. A. Climent, H. Cortes-Funes, A. Lluch, P. Gascon, J. I. Mayordomo, M. Gil, M. Benavides, L. Cirera, et al. (2009)
Clin. Cancer Res. 15, 307-314
 |  Abstract »  |  Full Text »  |  PDF »

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations.

M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano (2009)
Oncologist 14, 1-11
 |  Abstract »  |  Full Text »  |  PDF »

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer.

M. Dowsett and A. K. Dunbier (2008)
Clin. Cancer Res. 14, 8019-8026
 |  Abstract »  |  Full Text »  |  PDF »

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers.

S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon (2008)
J. Clin. Oncol. 26, 5697-5704
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Assay to Assess the Effectiveness of Antiangiogenic Drugs in Human Breast Cancer.

J. M. Lyons III, C. T. Anthony, J. L. Thomson, and E. A. Woltering (2008)
Ann. Surg. Oncol. 15, 3407-3414
 |  Abstract »  |  Full Text »  |  PDF »

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235.

P. J.A. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. Beijersbergen, V. Valero, J. Seoane, R. Bernards, et al. (2008)
Cancer Res. 68, 9221-9230
 |  Abstract »  |  Full Text »  |  PDF »

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate.

G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. (2008)
Cancer Res. 68, 9280-9290
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy.

S. Kyoda, S. Kinoshita, H. Takeyama, K. Uchida, and T. Morikawa (2008)
Jpn. J. Clin. Oncol. 38, 743-747
 |  Abstract »  |  Full Text »  |  PDF »

Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?.

M. J. Arranz and S. Kapur (2008)
Schizophr Bull 34, 1130-1144
 |  Abstract »  |  Full Text »  |  PDF »

Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists.

A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. (2008)
J. Mol. Diagn. 10, 527-536
 |  Abstract »  |  Full Text »  |  PDF »

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella (2008)
Ann. Onc. 19, 1860-1869
 |  Abstract »  |  Full Text »  |  PDF »

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors.

F. L. Chen, W. Xia, and N. L. Spector (2008)
Clin. Cancer Res. 14, 6730-6734
 |  Abstract »  |  Full Text »  |  PDF »

Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer.

C.-H. Yeh, W. A. Whitmire III, and M. Albitar (2008)
Clin. Chem. 54, 1831-1839
 |  Abstract »  |  Full Text »  |  PDF »

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.

R. J. Leary, J. C. Lin, J. Cummins, S. Boca, L. D. Wood, D. W. Parsons, S. Jones, T. Sjoblom, B.-H. Park, R. Parsons, et al. (2008)
PNAS 105, 16224-16229
 |  Abstract »  |  Full Text »  |  PDF »

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing.

I. Vanden Bempt, P. Van Loo, M. Drijkoningen, P. Neven, A. Smeets, M.-R. Christiaens, R. Paridaens, and C. De Wolf-Peeters (2008)
J. Clin. Oncol. 26, 4869-4874
 |  Abstract »  |  Full Text »  |  PDF »

Polysomy 17 and HER-2 Amplification: True, True, and Unrelated.

C. L. Rosenberg (2008)
J. Clin. Oncol. 26, 4856-4858
 |  Full Text »  |  PDF »

Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer.

J. K. Miller, D. L. Shattuck, E. Q. Ingalla, L. Yen, A. D. Borowsky, L. J.T. Young, R. D. Cardiff, K. L. Carraway III, and C. Sweeney (2008)
Cancer Res. 68, 8286-8294
 |  Abstract »  |  Full Text »  |  PDF »

Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2.

L. Menotti, A. Cerretani, H. Hengel, and G. Campadelli-Fiume (2008)
J. Virol. 82, 10153-10161
 |  Abstract »  |  Full Text »  |  PDF »

Poor-Prognosis Estrogen Receptor-Positive Breast Cancer Identified by Histopathologic Subclassification.

L. R. Webster, S.-F. Lee, C. Ringland, A. L. Morey, A. M. Hanby, G. Morgan, K. Byth, P. A. Mote, P. J. Provan, I. O. Ellis, et al. (2008)
Clin. Cancer Res. 14, 6625-6633
 |  Abstract »  |  Full Text »  |  PDF »

Studying copy number variations using a nanofluidic platform.

J. Qin, R. C. Jones, and R. Ramakrishnan (2008)
Nucleic Acids Res. 36, e116
 |  Abstract »  |  Full Text »  |  PDF »

N-Glycans in cancer progression.

K. S Lau and J. W Dennis (2008)
Glycobiology 18, 750-760
 |  Abstract »  |  Full Text »  |  PDF »

Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.

J. Sarup, P. Jin, L. Turin, X. Bai, M. Beryt, C. Brdlik, J. N. Higaki, B. Jorgensen, F. W. Lau, P. Lindley, et al. (2008)
Mol. Cancer Ther. 7, 3223-3236
 |  Abstract »  |  Full Text »  |  PDF »

Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.

D. J. Barr, A. G. Ostermeyer-Fay, R. A. Matundan, and D. A. Brown (2008)
J. Cell Sci. 121, 3155-3166
 |  Abstract »  |  Full Text »  |  PDF »

Validation of Analytic Methods for Biomarkers Used in Drug Development.

C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg (2008)
Clin. Cancer Res. 14, 5967-5976
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab-Induced Hepatotoxicity.

S. Srinivasan, V. Parsa, C. Y Liu, and J. A Fontana (2008)
Ann. Pharmacother. 42, 1497-1501
 |  Abstract »  |  Full Text »  |  PDF »

Epidermal growth factor receptor-targeted therapy.

C M West, L Joseph, and S Bhana (2008)
Br. J. Radiol. 81, S36-S44
 |  Abstract »  |  Full Text »  |  PDF »

DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies.

P. J. Whittington, M. P. Piechocki, H. H. Heng, J. B. Jacob, R. F. Jones, J. B. Back, and W.-Z. Wei (2008)
Cancer Res. 68, 7502-7511
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer.

M. Schmidt, D. Hasenclever, M. Schaeffer, D. Boehm, C. Cotarelo, E. Steiner, A. Lebrecht, W. Siggelkow, W. Weikel, I. Schiffer-Petry, et al. (2008)
Clin. Cancer Res. 14, 5849-5855
 |  Abstract »  |  Full Text »  |  PDF »

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter (2008)
Ann. Onc. 19, 1530-1539
 |  Abstract »  |  Full Text »  |  PDF »

Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/neu-targeted Therapy.

M. S. Gee, R. Upadhyay, H. Bergquist, H. Alencar, F. Reynolds, M. Maricevich, R. Weissleder, L. Josephson, and U. Mahmood (2008)
Radiology 248, 925-935
 |  Abstract »  |  Full Text »  |  PDF »

Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo.

Y. Zhang, P. J. Kaplan-Lefko, K. Rex, Y. Yang, J. Moriguchi, T. Osgood, B. Mattson, A. Coxon, M. Reese, T.-S. Kim, et al. (2008)
Cancer Res. 68, 6680-6687
 |  Abstract »  |  Full Text »  |  PDF »

B-Vitamin Intake, One-Carbon Metabolism, and Survival in a Population-Based Study of Women with Breast Cancer.

X. Xu, M. D. Gammon, J. G. Wetmur, P. T. Bradshaw, S. L. Teitelbaum, A. I. Neugut, R. M. Santella, and J. Chen (2008)
Cancer Epidemiol. Biomarkers Prev. 17, 2109-2116
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Factors in Metastatic Breast Cancer: Successes and Challenges Toward Individualized Therapy.

E. Andreopoulou and G. N. Hortobagyi (2008)
J. Clin. Oncol. 26, 3660-3662
 |  Full Text »  |  PDF »

Progesterone Receptor Inhibits Aromatase and Inflammatory Response Pathways in Breast Cancer Cells via Ligand-Dependent and Ligand-Independent Mechanisms.

D. B. Hardy, B. A. Janowski, C.-C. Chen, and C. R. Mendelson (2008)
Mol. Endocrinol. 22, 1812-1824
 |  Abstract »  |  Full Text »  |  PDF »

Targeting Src in breast cancer.

R. S. Finn (2008)
Ann. Onc. 19, 1379-1386
 |  Abstract »  |  Full Text »  |  PDF »

Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.

C B Nunes, R M Rocha, J S Reis-Filho, M B Lambros, G F S Rocha, F S F Sanches, F N Oliveira, and H Gobbi (2008)
J. Clin. Pathol. 61, 934-938
 |  Abstract »  |  Full Text »  |  PDF »

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer.

Q. S.C. Chu, M. E. Cianfrocca, L. J. Goldstein, M. Gale, N. Murray, J. Loftiss, N. Arya, K. M. Koch, L. Pandite, R. A. Fleming, et al. (2008)
Clin. Cancer Res. 14, 4484-4490
 |  Abstract »  |  Full Text »  |  PDF »

Breast Cancer in Young Women: A New Color or a Different Shade of Pink?.

J. Peppercorn and A. H. Partridge (2008)
J. Clin. Oncol. 26, 3303-3305
 |  Full Text »  |  PDF »

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer.

A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock, S. F. Jones, J. Loftiss, N. Arya, K. M. Koch, E. Paul, et al. (2008)
J. Clin. Oncol. 26, 3317-3323
 |  Abstract »  |  Full Text »  |  PDF »

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

D. Zhang, A. Pal, W. G. Bornmann, F. Yamasaki, F. J. Esteva, G. N. Hortobagyi, C. Bartholomeusz, and N. T. Ueno (2008)
Mol. Cancer Ther. 7, 1846-1850
 |  Abstract »  |  Full Text »  |  PDF »

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.

D. L. Rowe, T. Ozbay, L. M. Bender, and R. Nahta (2008)
Mol. Cancer Ther. 7, 1900-1908
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products